Table IV.
Covariate balance within quintiles for propensity score analysis
| Quintile | N |
History of asthma, % |
History of seasonal allergy, % |
Female, % |
Age, years, mean |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab | MTX | Dupilumab | MTX | Dupilumab | MTX | Dupilumab | MTX | Dupilumab | MTX | |
| 1 | 162 | 338 | 2.5% | 2.7% | 11.1% | 9.2% | 72.2% | 81.7% | 73.0 | 74.6 |
| 2 | 221 | 266 | 8.6% | 12.0% | 18.1% | 17.7% | 63.8% | 49.6% | 61.5 | 65.1 |
| 3 | 288 | 204 | 14.9% | 20.1% | 22.2% | 23.0% | 51.4% | 51.0% | 52.4 | 53.6 |
| 4 | 368 | 119 | 29.4% | 29.4% | 28.3% | 29.4% | 49.7% | 52.1% | 40.2 | 41.3 |
| 5 | 382 | 108 | 51.8% | 35.2% | 55.8% | 46.3% | 37.2% | 46.3% | 27.3 | 18.0 |
| Overall | 1421 | 1035 | 26.2% | 15.0% | 30.9% | 20.3% | 51.4% | 60.3% | 46.3 | 58.3 |
MTX, Methotrexate.